Compare AbbVie Inc (ABBV) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs TotalEnergies SE — how do they compare? AbbVie Inc trades at $253.03 (market cap $449.91B), while TotalEnergies SE trades at $78.9 (market cap $171.68B). The key difference: AbbVie Inc is far larger — about 2.6× TotalEnergies SE's market cap, and TotalEnergies SE pays the higher dividend (5.41%). Which is the better fit depends on your goals.
| ABBV | TTE | |
|---|---|---|
Market Cap | $449.91B | $171.68B |
Sector | Health | Energy |
52-Week High | $261.07 | $93.60 |
52-Week Low | $184.85 | $57.39 |
Enterprise Value | $513.38B | $205.82B |
Dividend Yield | 2.72% | 5.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $251.81, down 1.16% on the day, with strong analyst support showing 68% buy ratings and a $266.33 consensus price target. The stock exhibits bullish technical momentum with recent earnings beats in Q3 2025 through Q1 2026, though Q2 2026 expectations are set at $3.79 EPS. Revenue growth remains solid with 2025 reaching $61.16B, while profitability metrics show a 70.68% gross margin offset by a thinner 5.79% net margin. Recent news highlights pipeline strength with positive Phase 2 ovarian cancer data and institutional accumulation.
The outlook for ABBV is positive driven by robust immunology drugs Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s present long-term risks. Current valuation multiples appear elevated with P/E at 124.83 and P/B at 245.29, requiring sustained execution to justify premiums. Dividend reliability with recent $1.73 payments supports income investors, while technical resistance near $259-266 may cap near-term gains.
TotalEnergies (TTE) trades at $77.96, up 1.66% with a bearish technical signal despite recent earnings beat. The stock shows attractive valuation with P/E of 11.32 and P/S of 0.91, supported by stable dividends. Revenue declined to $182.34B in 2025 but net margins improved to 8.2%. Recent developments include new exploration contracts and strategic divestments, while cash flow trends show recovery with 2026 projection of $2.9B net cash flow.
Outlook remains cautiously optimistic given strong analyst buy ratings (57.58%) and value metrics, though bearish technicals and revenue declines pose near-term risks. The company's strategic moves in gas fields and emissions technology provide growth avenues, but regulatory pressures and oil price volatility require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
